How many stocks does RA CAPITAL MANAGEMENT, L.P. own?

As of Q4 2025, RA CAPITAL MANAGEMENT, L.P. holds 71 positions in their 13F portfolio.

What is RA CAPITAL MANAGEMENT, L.P.'s largest holding?

ASND at 22.5% of portfolio, worth $2.2B.

What is RA CAPITAL MANAGEMENT, L.P.'s total portfolio value?

$9.8B as of Q4 2025, tracked across 71 holdings.

Is RA CAPITAL MANAGEMENT, L.P. a hedge fund?

RA CAPITAL MANAGEMENT, L.P. is an institutional investment manager required to file SEC 13F reports. This includes hedge funds, mutual funds, pension funds, and other institutions managing over $100M.

How often does RA CAPITAL MANAGEMENT, L.P. report?

13F filings are due quarterly, approximately 45 days after each quarter end.

How has RA CAPITAL MANAGEMENT, L.P.'s portfolio changed in Q4 2025?

View RA CAPITAL MANAGEMENT, L.P.'s latest portfolio changes, new positions, and exits for Q4 2025 on HoldingsIntel.

What is RA CAPITAL MANAGEMENT, L.P.'s investment strategy?

RA CAPITAL MANAGEMENT, L.P. is classified as a Balanced Allocator fund based on HoldingsIntel's Fund DNA analysis of 6 behavioral dimensions.

RA CAPITAL MANAGEMENT, L.P. Holdings Q4 2025 - Portfolio & Conviction Scores | HoldingsIntel

RA CAPITAL MANAGEMENT, L.P.

Institutional investor · Portfolio as of Q4 2025

Solid(2.5 / 5.0)

$9.8B

AUM

Positions

New

Q4 2025

Filing Period

Quarterly Portfolio Change

SEC EDGAR SourceSEC Filings

RA CAPITAL MANAGEMENT, L.P. manages $9.8B across 71 positions as of Q4 2025. Top holdings: ASND (22.5%), CDTX (7.6%), RYTM (7.3%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 2.5/5.0.

Q4 2025 Summary

Active quarter - 22 new positions, 18 exits, 13 increased. Top move: RYTM (INCREASED, conviction 72). Portfolio: $9.8B across 71 positions.

Portfolio Allocation

Top holdings by portfolio weight

ASND22.46%

CDTX7.62%

RYTM7.31%

RNA6.39%

PCVX5.07%

SION4.17%

NAMS3.43%

TYRA3.29%

WVE3.17%

MLYS2.72%

Other2.65%

Similar Funds

Funds with similar investing DNA

Temasek Holdings (Private) Ltd

$31B

FRED ALGER MANAGEMENT, LLC

$25.5B

+3 more

Position Outcomes

Best and worst performing positions by estimated return

Top Winners

CDTX6Q held

CIDARA THERAPEUTICS INC

Avg $38.56 · $615.3M est. P&L

Est. P&L

+474.10%

SION4Q held

Sionna Therapeutics, Inc.

Avg $11.56 · $223.2M est. P&L

Est. P&L

+194.90%

ASND29Q held

Ascendis Pharma A/S

Avg $95.48 · $1.5B est. P&L

Est. P&L

+150.55%

Top Losers

Upgrade to Pro to see the worst-performing positions.

View plans

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Top Holdings10 of 71

Export CSV(Pro)

Activity:

Stock	Shares	Value	Weight	Price Trend	Avg Buy	Est. P&L	Held	Conviction
ASNDADR Ascendis Pharma A/S	10.3M	$2.2B	22.5%	—	$95.48	+150.55%	29 qtrssince 2018-Q4	Unchanged 0
CDTX CIDARA THERAPEUTICS INC	3.4M	$743.4M	7.6%	—	$38.56	+474.10%	6 qtrssince 2024-Q3	Unchanged 0
RYTM Rhythm Pharmaceuticals, Inc.	6.7M	$713.6M	7.3%	—	$38.85	+130.51%	29 qtrssince 2018-Q4	Increased 72
RNA Atrium Therapeutics, Inc.	8.6M	$623.3M	6.4%	—	$32.67	-52.03%	18 qtrssince 2021-Q3	Unchanged 0
PCVX Vaxcyte, Inc.	10.7M	$494.8M	5.1%	—	$49.07	+21.91%	23 qtrssince 2020-Q2	Decreased 0
SION Sionna Therapeutics, Inc.	9.9M	$407.5M	4.2%	—	$11.56	+194.90%	4 qtrssince 2025-Q1	Decreased 0
NAMS NewAmsterdam Pharma Company N.V	9.6M	$335M	3.4%	—	$14.11	+115.55%	13 qtrssince 2022-Q4	Decreased 0
TYRA Tyra Biosciences, Inc.	12.2M	$320.7M	3.3%	—	$15.72	+109.95%	18 qtrssince 2021-Q3	Unchanged 0
WVE Wave Life Sciences Ltd.	18.2M	$309.5M	3.2%	—	$19.79	-32.10%	29 qtrssince 2018-Q4	Increased 57
MLYS Mineralys Therapeutics, Inc.	7.3M	$265.8M	2.7%	—	$18.66	+52.82%	12 qtrssince 2023-Q1	Unchanged 0
Showing 10 of 71 results.61 more with Pro.PROUpgrade to see all →